Results 31 to 40 of about 136,011 (340)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Pharmaceuticals, 2020
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA.
Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi   +7 more
doaj   +1 more source

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits [PDF]

International Journal of Ophthalmology, 2015
AIM:To investigate the pharmacokinetics and distributions of bevacizumab by intravitreal injection of prepared bevacizumab-poly (L-lactic-co-glycolic acid) (PLGA) microspheres in rabbits, to provide evidence for clinical application of this kind of ...
Zhuo Ye, Yan-Li Ji, Xiang Ma, Jian-Guo Wen, Wei Wei, Shu-Man Huang   +5 more
doaj   +1 more source

The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]

, 2013
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique, Denys, Hannelore, KRUSE, VIBEKE, Van Belle, Simon, Van den Broecke, Rudy   +4 more
core   +2 more sources

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

JAMA Network Open, 2021
Key Points Question Compared with sorafenib, is atezolizumab plus bevacizumab cost-effective as first-line treatment of unresectable hepatocellular carcinoma?
D. Su, Bin Wu, Lizheng Shi
semanticscholar   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization

Veterinary Sciences, 2023
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to ...
Ulrike Lessiak, Barbara Pratscher, Alexander Tichy, Barbara Nell   +3 more
doaj   +1 more source

Salvage Fractionated Stereotactic Re-irradiation (FSRT) for Patients with Recurrent High Grade Gliomas Progressed after Bevacizumab Treatment [PDF]

, 2017
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage- ment of high grade gliomas (HGG), with a median overall survival of less than 4 months (m).
Andrews MD, David W., Bar-Ad, Voichita, Bhamidipati, Deepak, Blomain, Erik S, Dan, Tu, Evans, James J., Farrell, MD, Christopher J, Glass, MD, Jon, Judy, MD, Kevin, Kim, Lyndon, Palmer, Joshua, Shi, Wenyin, Siglin, Joshua, Wang, Yang, Werner-Wasik, Maria   +14 more
core   +2 more sources

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

New England Journal of Medicine, 2006
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a ...
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David H. Johnson   +7 more
semanticscholar   +1 more source

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. [PDF]

, 2018
BackgroundWe performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.MethodsPatients were given fixed dose gemcitabine plus ...
Agarwal, Rishi, Bass, Allison, Bean, Stacie, Byers, Lauren, Falchook, Gerald, Fu, Siqing, Hess, Kenneth, Hong, David, Janku, Filip, Karp, Daniel, Kato, Shumei, Kurzrock, Razelle, Lim, JoAnn, Meric-Bernstam, Funda, Naing, Aung, Nguyen, Ly, Pant, Shubham, Piha-Paul, Sarina, Sen, Shiraj, Subbiah, Vivek, Tang, Chad, Tsimberidou, Apostolia, Westin, Shannon, Wu, Xifeng, Ye, Yuanqing   +24 more
core   +2 more sources

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

JAMA Oncology, 2021
This randomized clinical trial assesses the efficacy and safety of osimertinib plus bevacizumab vs osimertinib alone in patients with EGFR T790M–mutated lung adenocarcinoma.
H. Akamatsu, Y. Toi, H. Hayashi, D. Fujimoto, M. Tachihara, N. Furuya, S. Otani, J. Shimizu, N. Katakami, K. Azuma, N. Miura, K. Nishino, S. Hara, S. Teraoka, S. Morita, K. Nakagawa, N. Yamamoto   +16 more
semanticscholar   +1 more source